Which beta blocker is described as preferred in the setting of cardiac disease?

Which beta blocker is described as preferred in the setting of cardiac disease?

• A. Labetalol
• B. Esmolol
• C. Metoprolol
• D. Propranolol

Answer: (A)

In cardiac disease, you want a beta-blocker that lowers afterload while protecting the heart, and labetalol fits that balance because it blocks both alpha1 and beta receptors. The alpha blockade reduces systemic vascular resistance, which lowers blood pressure without a large drop in cardiac output, while the beta blockade helps control heart rate and myocardial workload. This combination makes labetalol a safer, more versatile choice in patients with cardiac disease, including pregnancy-related cardiac concerns, compared with agents that are purely beta-blockers or those with less favorable fetal and hemodynamic profiles. Esmolol is mainly for acute, short-term rate control; propranolol is nonselective and crosses the placenta readily, posing more fetal risks; metoprolol is cardioselective but may still carry concerns in pregnancy and is not as multitargeted in hemodynamics as labetalol.

In cardiac disease, you want a beta-blocker that lowers afterload while protecting the heart, and labetalol fits that balance because it blocks both alpha1 and beta receptors. The alpha blockade reduces systemic vascular resistance, which lowers blood pressure without a large drop in cardiac output, while the beta blockade helps control heart rate and myocardial workload. This combination makes labetalol a safer, more versatile choice in patients with cardiac disease, including pregnancy-related cardiac concerns, compared with agents that are purely beta-blockers or those with less favorable fetal and hemodynamic profiles. Esmolol is mainly for acute, short-term rate control; propranolol is nonselective and crosses the placenta readily, posing more fetal risks; metoprolol is cardioselective but may still carry concerns in pregnancy and is not as multitargeted in hemodynamics as labetalol.